Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(2):97; doi:10.1093/jnci/djk060
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Widener, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Widener, A.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

MEMO TO THE MEDIA

Press Release

No Benefit to Increasing Dose Intensity of Chemotherapy in Osteosarcoma, Study Finds

Andrea Widener

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

A dose-intensive regimen of the chemotherapy drugs cisplatin and doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcoma, according to results from a randomized trial in the January 17 issue of the Journal of the National Cancer Institute. Although the dose-intensive regimen killed tumor cells better than the standard regimen after surgery, survival rates were similar in both . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup
Ian J. Lewis, Marianne A. Nooij, Jeremy Whelan, Matthew R. Sydes, Robert Grimer, Pancras C. W. Hogendoorn, Muhammad A. Memon, Simon Weeden, Barbara M. Uscinska, Martine van Glabbeke, Anne Kirkpatrick, Esther I. Hauben, Alan W. Craft, and Antonie H. M. Taminiau
J Natl Cancer Inst 2007 99: 112-128. [Abstract] [Full Text] [PDF]

Response Rate as an Endpoint in Clinical Trials
Stephen L. George
J Natl Cancer Inst 2007 99: 98-99. [Extract] [Full Text] [PDF]